Back to results

CompletedPhase 2

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

NCT03671330

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Hefei, Anhui, China

+23 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2018-08-29
Enrollment: 327 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (24)

Novartis Investigative SiteHefei, Anhui, China
Novartis Investigative SiteBeijing, Beijing Municipality, China
Novartis Investigative SiteChongqing, Chongqing Municipality, China
Novartis Investigative SiteGuangzhou, Guangdong, China
Novartis Investigative SiteShijiazhuang, Hebei, China
Novartis Investigative SiteHarbin, Heilongjiang, China
Novartis Investigative SiteChangsha, Hunan, China
Novartis Investigative SiteNanjing, Jiangsu, China
Novartis Investigative SiteSuzhou, Jiangsu, China
Novartis Investigative SiteNanchang, Jiangxi, China
Novartis Investigative SiteChangchun, Jilin, China
Novartis Investigative SiteShengyang, Liaoning, China
Novartis Investigative SiteShengyang, Liaoning, China
Novartis Investigative SiteXian, Shanxi, China
Novartis Investigative SiteChengdu, Sichuan, China
Novartis Investigative SiteKunming, Yunnan, China
Novartis Investigative SiteHangzhou, Zhejiang, China
Novartis Investigative SiteHangzhou, Zhejiang, China
Novartis Investigative SiteBeijing, China
Novartis Investigative SiteFuzhou, China
Novartis Investigative SiteQingdao, China
Novartis Investigative SiteShanghai, China
Novartis Investigative SiteShanghai, China
Novartis Investigative SiteTianjin, China

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. — TrialFind